|
|
|
|
|
|
|
|
full text - open access:
The Status of Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer, Part 2: Extending the Scope Beyond Olaparib and BRCA1/2 Mutations
Sept 2016
Abstract
Poly(adenosine
diphosphate-ribose) polymerase (PARP) inhibitors have shown clinical
activity in epithelial ovarian cancer, leading both the US Food and Drug
Administration (FDA) and the European Medicines Agency to approve
olaparib for tumors characterized by BRCA1 and BRCA2 mutations. However,
it is becoming increasingly evident that tumors that share molecular
features with BRCA-mutant tumors-a concept known as BRCAness-also may
exhibit defective homologous recombination DNA repair, and therefore
will respond to PARP inhibition. A number of strategies have been
proposed to identify BRCAness, including identifying defects in other
genes that modulate homologous recombination and characterizing the
mutational and transcriptional signatures of BRCAness. In addition to
olaparib, a number of other PARP inhibitors are in clinical development.
This article reviews the development of PARP inhibitors other than
olaparib, and discusses the evidence for PARP inhibitors beyond
BRCA1/2-mutant ovarian cancer.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.